Sight Sciences SEC filings document the company’s ophthalmic medical device business, segment operating results, governance, capital structure, and material events. Form 8-K filings report quarterly and annual financial results, investor presentation materials, and Regulation FD disclosures tied to the company’s Interventional Glaucoma and Interventional Dry Eye operations.
The filing record also includes definitive proxy materials for annual meeting matters, disclosures on executive officer changes and compensatory arrangements, material agreements such as lease amendments, and legal disclosures involving interventional glaucoma patents. These filings frame SGHT’s public reporting around product commercialization, intellectual property, corporate governance, risk factors, and shareholder voting matters.
Sight Sciences, Inc. (SGHT) common shares are the subject of former officer Jeremy B. Hayden’s proposed sale of 26,000 shares, with an aggregate market value of $260,521.00 and an approximate sale date of November 5, 2026. Fidelity Brokerage Services LLC and Nasdaq are listed in the sale details.
Sight Sciences, Inc. (SGHT) reported third-quarter 2026 revenue of $24.9 million, up 25.2% from $19.9 million a year earlier. Gross profit was $21.4 million; gross margin was 85.9%, versus 86.4%. Net loss narrowed to $6.8 million from $8.2 million, and operating loss was $6.1 million versus $7.9 million. For the first nine months, revenue was $68.0 million, up 19.4%, while net loss was $24.2 million versus $34.3 million.
Cash and cash equivalents were $77.4 million at September 30, 2026, and operating activities used $15.1 million over the nine months. Debt outstanding was $41.0 million at September 30, 2026. In October 2026, Sight Sciences and Hercules amended the loan agreement, extending its interest-only period by six months, from February 1, 2027, to August 1, 2027. Sight Sciences believes its cash and other existing liquidity sources will satisfy working-capital and capital-resource requirements for at least 12 months from issuance of the statements; it expects losses for at least the next several years.
A court's April 22, 2026 final judgment awarded Sight Sciences $55.4 million and an ongoing royalty of 10% of Hydrus revenue through expiration of the last patent. Alcon appealed; briefing was expected to conclude in early 2027. The USPTO issued a reexamination certificate for one patent on October 27, 2026, while a reexamination of another patent remained pending.
Sight Sciences, Inc. (SGHT) reported third-quarter 2026 revenue of $24.9 million, up 25% year over year. Interventional Glaucoma revenue was $21.0 million, up 7%; Interventional Dry Eye revenue was $3.9 million, versus $0.2 million a year earlier. Gross margin was 86%.
Net loss improved 17% to $6.8 million from $8.2 million; loss per share was $0.12 versus $0.16. Operating expenses were $27.5 million, up 10%. Cash and cash equivalents were $77.4 million and total debt, excluding unamortized discount and debt issuance costs, was $40.0 million as of September 30, 2026. Cash usage was $2.4 million, down 74% from $9.1 million a year earlier.
The company raised full-year 2026 revenue guidance to $92 million to $93 million, representing 19% to 20% growth, versus prior guidance of $88 million to $92 million. The outlook includes $80 million to $81 million from Interventional Glaucoma and approximately $12 million from Interventional Dry Eye. Adjusted operating expense guidance remained $92 million to $94 million, up 5% to 7% versus 2025. Sight Sciences also launched the OMNI Ultra Surgical System at the American Academy of Ophthalmology annual meeting.
Taylor Brenton, Sight Sciences’ EVP, Operations & R&D, sold 2,988 shares of Common Stock on October 2, 2026, to cover tax liability connected with vesting of RSUs. The weighted average sale price was $8.853 per share, and the transaction was made under a Rule 10b5-1 plan. After the sale, reported holdings were 261,990 shares, including 41,602 shares of Common Stock and 220,388 shares to be acquired upon vesting and settlement of unvested RSUs.
Sight Sciences, Inc. (SGHT) Chief Operating Officer Alison Bauerlein sold 25,260 shares on October 2, 2026, at a weighted average price of $8.8530 per share. The shares were sold to cover tax liability in connection with the vesting of restricted stock units, and the transaction was made pursuant to a Rule 10b5-1 plan. After the sale, Bauerlein reported 639,449 shares, including 214,450 shares of common stock and 424,999 shares to be acquired upon vesting and settlement of unvested RSUs.
Sight Sciences, Inc. (SGHT) Chief Financial Officer James Rodberg sold 7,208 shares of Common Stock on October 2, 2026, at a weighted average price of $8.8530 per share to cover tax liability connected with vesting of restricted stock units. The sale was made under a Rule 10b5-1 plan. His reported post-transaction position was 216,829 shares, including 62,932 shares of Common Stock and 153,897 shares issuable upon vesting and settlement of unvested RSUs.
Sight Sciences, Inc. Chief Technology Officer and director David Badawi sold 7,797 common shares on October 1, 2026, at a weighted average price of $9.0490 per share to cover tax liability in connection with RSU vesting. The sale was made under a Rule 10b5-1 plan. His reported post-transaction position was 1,975,075 shares, including 1,823,160 common shares and 151,915 shares to be acquired upon vesting and settlement of unvested RSUs.
Sight Sciences, Inc. President and CEO Paul Badawi sold 29,653 shares of common stock on October 1, 2026, at a weighted average price of $9.0490 per share to cover tax liability associated with RSU vesting. The sale was made under a Rule 10b5-1 plan. Afterward, his reported position was 6,092,819 shares, including 5,599,542 shares of common stock and 493,277 shares to be acquired upon vesting and settlement of unvested RSUs.
Sight Sciences, Inc. (SGHT) officer Alison Bauerlein reported a proposed sale of 25,260 common shares, with an aggregate market value of $223,631.83 and an approximate sale date of October 2, 2026.
The shares resulted from restricted stock vesting as compensation on September 30, 2026. The remarks say the sale includes an amount needed to cover a tax obligation from settlement of a vested equity award distribution. Joshua Schmitt signed as Fidelity Brokerage Services LLC's representative and attorney-in-fact for Bauerlein.
Sight Sciences, Inc. officer Taylor Brenton submitted notice of a proposed sale of 2,988 common shares, with an aggregate market value of $26,453.37 and an approximate sale date of October 2, 2026. The shares relate to restricted-stock vesting on September 30, 2026, and the notice says the sale includes an amount needed to cover a tax obligation resulting from settlement of the vested equity award distribution.